Recent Highlights
- Generated
$26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. - Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.
- Raised approximately
$220 million in gross proceeds from our initial public offering inApril 2026 .
"We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said
First Quarter 2026 Financial Results
Revenue was
Gross margin was 56% for the first quarter of 2026, as compared to 49% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies realized through larger consumables production volumes, higher average selling prices across both instruments and consumables, and by a favorable shift in product mix toward higher-margin consumables.
Operating expenses were
Operating loss was
Net loss was
Cash, cash equivalents, and restricted cash were
Recent Developments
In April, after quarter end,
The company intends to provide full-year 2026 revenue guidance in conjunction with its second quarter 2026 earnings release in
About
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states.
Forward Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, anticipated timing and content regarding full-year 2026 guidance, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 21,341 | $ | 9,169 | ||||
| Service and other revenue | 4,694 | 3,922 | ||||||
| Total revenue(1) | 26,035 | 13,091 | ||||||
| Cost of revenue: | ||||||||
| Cost of product revenue(2) | 9,810 | 5,371 | ||||||
| Cost of service and other revenue(2) | 1,768 | 1,331 | ||||||
| Total cost of revenue | 11,578 | 6,702 | ||||||
| Gross profit | 14,457 | 6,389 | ||||||
| Operating expenses: | ||||||||
| Research and development(2) | 13,017 | 8,302 | ||||||
| Selling, general and administrative(2) | 13,787 | 6,640 | ||||||
| Total operating expenses | 26,804 | 14,942 | ||||||
| Loss from operations | (12,347 | ) | (8,553 | ) | ||||
| Interest income, net | 539 | 786 | ||||||
| Interest expense | (223 | ) | (46 | ) | ||||
| Loss on remeasurement of convertible notes | (8,594 | ) | — | |||||
| Other (expense) income, net | (236 | ) | 154 | |||||
| Net loss before income tax | (20,861 | ) | (7,659 | ) | ||||
| Provision for income taxes | 464 | — | ||||||
| Net loss | $ | (21,325 | ) | $ | (7,659 | ) | ||
| Net loss per share, basic and diluted | $ | (1.74 | ) | $ | (0.68 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 12,259,811 | 11,258,870 | ||||||
(1) The following table represents revenue by source for the periods indicated:
| Three Months Ended | ||||||||
| (in thousands) | 2026 | 2025 | ||||||
| Instruments | $ | 7,381 | $ | 4,146 | ||||
| Consumables | 13,960 | 5,023 | ||||||
| Services | 4,694 | 3,672 | ||||||
| Other revenue | — | 250 | ||||||
| Total | $ | 26,035 | $ | 13,091 | ||||
(2) Includes stock-based compensation expense as follows:
| Three Months Ended | ||||||||
| (in thousands) | 2026 | 2025 | ||||||
| Cost of product revenue | $ | 14 | $ | 8 | ||||
| Cost of service and other revenue | 22 | 13 | ||||||
| Research and development | 392 | 229 | ||||||
| Selling, general and administrative | 1,039 | 369 | ||||||
| Total stock-based compensation expense | $ | 1,467 | $ | 619 | ||||
Condensed Consolidated Balance Sheets (Unaudited, in thousands) | ||||||||||
2026 | 2025 | |||||||||
| ASSETS | ||||||||||
| Current Assets | ||||||||||
| Cash and cash equivalents | $ | 64,586 | $ | 30,002 | ||||||
| Accounts receivable | 19,524 | 12,753 | ||||||||
| Inventory | 39,931 | 38,482 | ||||||||
| Prepaid expenses and other current assets | 17,432 | 13,468 | ||||||||
| Total current assets | 141,473 | 94,705 | ||||||||
| Restricted cash | 4,907 | 4,907 | ||||||||
| Property and equipment, net | 10,472 | 10,498 | ||||||||
| Operating lease right-of-use assets | 25,671 | 26,130 | ||||||||
| Capitalized software, net | 1,836 | 1,988 | ||||||||
| Other assets—noncurrent | 2,092 | 1,764 | ||||||||
| Total assets | $ | 186,451 | $ | 139,992 | ||||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT | ||||||||||
| Current Liabilities | ||||||||||
| Accounts payable | $ | 5,635 | $ | 5,872 | ||||||
| Accrued and other current liabilities | 16,814 | 15,759 | ||||||||
| Short-term operating lease liabilities | 1,599 | 2,099 | ||||||||
| Total current liabilities | 24,048 | 23,730 | ||||||||
| Long-term operating lease liabilities | 28,979 | 29,564 | ||||||||
| Warrant liabilities | 331 | 247 | ||||||||
| Term debt | 9,877 | 9,810 | ||||||||
| Convertible note | 65,094 | — | ||||||||
| Other noncurrent liabilities | 1,197 | 599 | ||||||||
| Total liabilities | 129,526 | 63,950 | ||||||||
| Convertible preferred stock | 234,996 | 234,996 | ||||||||
| Stockholders’ deficit | ||||||||||
| Founders preferred stock | — | — | ||||||||
| Common stock | 1 | 1 | ||||||||
| Additional paid-in capital | 12,108 | 9,892 | ||||||||
| Accumulated other comprehensive loss | (80 | ) | (72 | ) | ||||||
| Accumulated deficit | (190,100 | ) | (168,775 | ) | ||||||
| Total stockholders’ deficit | (178,071 | ) | (158,954 | ) | ||||||
| Total liabilities, convertible preferred stock and stockholders' deficit | $ | 186,451 | $ | 139,992 | ||||||
